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Background: The glomerular podocyte is a highly specialized cell type with the ability to ultrafilter blood and
support glomerular capillary pressure. However, little is known about the genetic programs leading to this
functionality or the final phenotype.
Results: In the current study, we found that the expression of a myocardin/MKL family member, MKL1, was
significantly upregulated during cell cycle arrest induced by a temperature switch in murine podocyte clone 5
(MPC5) cells. Further investigation demonstrated that overexpression of MKL1 led to inhibition of cell proliferation
by decreasing the number of cells in S phase of the cell cycle. In contrast, MKL1 knockdown by RNA interference
had the opposite effect, highlighting a potential role of MKL1 in blocking G1/S transition of the cell cycle in MPC5
cells. Additionally, using an RT2 Profiler PCR Array, p21 was identified as a direct target of MKL1. We further revealed
that MKL1 activated p21 transcription by recruitment to the CArG element in its promoter, thus resulting in cell
cycle arrest. In addition, the expression of MKL1 is positively correlated with that of p21 in podocytes in postnatal
mouse kidney and significantly upregulated during the morphological switch of podocytes from proliferation to
differentiation.
Conclusions: Our observations demonstrate that MKL1 has physiological roles in the maturation and development
of podocytes, and thus its misregulation might lead to glomerular and renal dysfunction.
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Podocytes, also called visceral glomerular epithelial cells,
are terminally differentiated cells overlaying the outer re-
gion of the glomerular basement membrane of renal
glomeruli. These cells have several key functions includ-
ing the prevention of proteinuria, synthesis of basement
membrane components, regulation of glomerular filtra-
tion, and counteraction of intraglomerular hydrostatic
pressure [1]. Podocyte injury is typically associated with
proteinuria and progressive glomerulosclerosis [2].
Podocytes are derived from epithelial cells originating
in the metanephric mesenchyme, which develop into
postmitotic terminally differentiated cells, and therefore
have similarities to neurons [3,4]. During glomerulogen-
esis, podocytes proliferate until the S-shape body stage* Correspondence: yangshuang@nankai.edu.cn; zhuoyang@nankai.edu.cn
1Medical School, Tianjin Key Laboratory of Tumor Microenvironment and
Neurovascular Regulation, Nankai University, 94 Weijin Road, Tianjin 300071,
China
Full list of author information is available at the end of the article
© 2015 Yang et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.and exit the cell cycle at the capillary loop stage [5,6].
Podocytes then acquire their fully differentiated pheno-
type, a process that is not complete until 1 week after
birth in the mouse. Mature podocytes tightly regulate
and maintain their quiescent and differentiated pheno-
type, and therefore lost podocytes cannot be replaced by
proliferation of neighboring undamaged cells. Indeed,
studies have shown that the inability to proliferate con-
tributes to glomerular scarring [7]. Thus, the mechanism
responsible for the cell cycle arrest that occurs during
nephrogenesis may also participate in maintenance of
cell cycle quiescence in mature podocytes.
Megakaryoblastic leukemia 1 (MKL1) was originally
found in a study of a chromosomal translocation, t (1;22),
which is closely related to the incidence of acute mega-
karyoblastic leukemia in infants and children [8,9].
MKL1 has been recently shown to be a member of a
three-protein family that includes MKL2 and myocar-
din. These myocardin/MKL proteins serve as serum re-
sponse factor (SRF) coactivators by binding to SRF andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to myocardin, which has cardiac and smooth muscle-
specific expression [10,14-16], MKL1 and MKL2 are
expressed in a wide range of embryonic and adult tis-
sues [8,11,17-20]. MKL1 regulates many processes in-
cluding muscle cell differentiation [17], cardiovascular
development [18], remodeling of neuronal networks in
the developing and adult brain [19], megakaryocytic
differentiation and migration [21,22], modulation of cel-
lular motile functions, and epithelial-mesenchymal tran-
sition [23-25]. Notably, there is increasing evidence of
the involvement of the myocardin/MKL family in sup-
pression of cell proliferation and cell cycle progression.
Both myocardin and MKL1 exert anti-proliferative ef-
fects in various cell lines [26-28]. Therefore, unraveling
the functional pathways in which these proteins have a
role and furthering our comprehension of the cellular
mechanisms intrinsic to their regulation of cell prolifer-
ation will become increasingly important.
In the present study, we found that MKL1 expres-
sion was upregulated during temperature-switched
growth arrest in murine podocyte clone 5 (MPC5)
cells. Overexpression of MKL1 resulted in inhibition
of G1/S cell cycle progression in cell viability and EdU
cell proliferation assays, whereas MKL1 knockdown
had the opposite effect. We further demonstrated that
MKL1 induced expression of the cyclin-dependent kin-
ase inhibitor (CKI) p21 during the regulation of cell
cycle arrest. Importantly, MKL1 expression was ob-
served in podocytes of the mouse kidney during post-
natal development, which was upregulated during the
morphological switch of podocytes from proliferation
to differentiation.
Results
Expression of MKL1 is upregulated during
temperature-switched cell growth arrest in MPC5 cells
To assess the possible role of myocardin/MKL proteins
in podocyte growth arrest, MPC5 cells were respectively
maintained at the permissive temperature of 33°C and at
the nonpermissive temperature of 37°C for 10 days. As
shown in Figure 1A, a cell viability assay indicated that
MPC5 cells cultured at 37°C showed a significant de-
crease in cell number compared with those cultured at
33°C. The results of immunofluorescence staining in the
EdU cell proliferation assay further revealed a marked
decrease in the number of cells in S phase by the
temperature switch to 37°C (Figure 1B and C). The per-
centage of cells in S phase decreased from 46.37% to
20.03% as early as 2 days after the temperature switch.
At 4–6 days, the percentage of cells in S phase further
decreased from 14.97% to 6.70%, which is consistent
with a previous report indicating that the temperature
switch induces growth arrest of podocytes in vitro [29].The expression of myocardin/MKL proteins was then
measured during temperature-switched growth arrest
in MPC5 cells. qPCR analysis indicated that the tem-
perature switch to 37°C induced an approximate 1.8-fold
increase in MKL1 mRNA expression compared with the
basal level at 2 days (Figure 1D). At 4–10 days, MKL1
expression showed a 2-4-fold increase at the mRNA
level. Western blotting was used to confirm the up-
regulation of MKL1 expression at the protein level
(Figure 1E). However, the alteration in myocardin
and MKL2 expression was not as evident (Figure 1D).
Considering the dominant presence of MKL1 over its
other family members, we focused on the effects of MKL1
in subsequent experiments.
MKL1 functions as an effective inducer of cell growth
arrest in MPC5 cells
Next, a mouse MKL1 expression plasmid [11] was tran-
siently transfected into MPC5 cells. Overexpression of
MKL1 was assessed by western blotting (Figure 2A).
Compared with control cells, the cell viability assay indi-
cated that ectopic expression of MKL1 inhibited MPC5
cell proliferation (Figure 2B). Results of DNA analysis
by flow cytometry further confirmed that MKL1-
overexpressing MPC5 cells had a lower population of
S phase cells and a higher population of G0/G1 phase
cells (Additional file 1: Figure S1). The EdU cell pro-
liferation assay revealed a marked decrease in the
number of S phase cells after MKL1 overexpression
(Figure 2C). The percentage of cells in S phase de-
creased from 55.56% to 28.39% at 72 h after transfec-
tion of the MKL1 expression plasmid. Furthermore,
MPC5 cells were stably transfected with either the
MKL1 expression plasmid (ΔMKL1) or the empty vec-
tor (ΔControl). Overexpression of MKL1 was then ex-
amined by western blotting (Figure 2D). Cell viability
and EdU cell proliferation assays confirmed that MKL1
overexpression induced a delay in G1/S phase transi-
tion of MPC5 cells (Figure 2E and F).
Therefore, we hypothesized that knockdown of MKL1
by RNA interference would result in an increase in the
number of cells in S phase. To test our hypothesis, a
MKL1-targeting shRNA plasmid (shMKL1) or a scram-
bled control shRNA plasmid (shControl) were transi-
ently transfected into MPC5 cells. Knockdown of
MKL1 expression was confirmed by western blotting
(Figure 3A). Compared with shControl cells, the cell
viability assay indicated that depletion of MKL1 pro-
moted MPC5 cell proliferation (Figure 3B). The results of
DNA analysis by flow cytometry further showed that
MKL1 knockdown MPC5 cells had a higher population
of cells in S phase and a lower population of cells in G0/
G1 phase compared with control cells (Additional file 2:
Figure S2). The EdU cell proliferation assay revealed that
Figure 1 MKL1 is upregulated during temperature-switched cell cycle arrest in MPC5 cells. A) MPC5 cells were cultured at the permissive
temperature of 33°C or the nonpermissive temperature of 37°C. At the indicated time points, cell growth was measured using a CCK-8 assay.
**p < 0.01 compared with the control (one-way ANOVA followed by Tukey’s HSD test). B) MPC5 cells were shifted from 33°C to 37°C and cultured
for the indicated times. Cell proliferation was measured by immunofluorescence analysis of EdU incorporation. Scale bars, 25 μm. C) The percentage
of proliferating cells was calculated as EdU-positive cells/Hoechst-stained cells × 100%. **p < 0.01 compared with the control (one-way ANOVA
followed by Tukey’s HSD test). D) MPC5 cells were shifted from 33°C to 37°C and cultured for the indicated times. The mRNA expression levels of
myocardin, MKL1 and MKL2 were verified by qPCR. GAPDH was used to normalize expression levels. *p < 0.05 compared with the control (one-way
ANOVA followed by Tukey’s HSD test). E) MPC5 cells were shifted from 33°C to 37°C and cultured for the indicated times. Protein expression levels
of MKL1 were examined by western blotting. Actin was used to normalize MKL1 levels.
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the number of cells in S phase from 47.40% to 77.07% at
72 h after MKL1 knockdown (Figure 3C). In addition,
MPC5 cells were stably transfected with either shMKL1
(ΔshMKL1) or shControl (ΔshControl). Knockdown of
MKL1 expression was then confirmed by western blotting
(Figure 3D). The cell viability and EdU cell proliferation as-
says confirmed that repression of MKL1 remarkably pro-
moted cell cycle progression through S phase in MPC5
cells (Figure 3E and F).MKL1 regulates podocyte proliferation by targeting p21
To identify the potential cellular pathways regulated by
MKL1, differences in the mRNA levels of selected sig-
naling molecules were examined using an RT2 Profiler
PCR Array by comparing MKL1-expressing MPC5 cells
with the control cells. We observed alterations in the ex-
pression of several cell cycle regulators, including p21,
Gadd45a, Ddit3, E2F2, and cyclin A1 (Table 1). qPCR
and western blotting were performed to verify these
findings (Figure 4A and Additional file 3: Figure S3).
Figure 2 Overexpression of MKL1 induces MPC5 cell growth arrest. A) MPC5 cells were transiently transfected with a mouse MKL1 expression
plasmid and cultured at 33°C. Expression of MKL1 protein was verified by western blotting. Actin was used to normalize MKL1 levels. B) At the indicated
time points, cell growth was measured using the CCK-8 assay. *p< 0.05 and **p < 0.01 compared with the control (one-way ANOVA followed by Tukey’s
HSD test). C) Cell proliferation was measured by immunofluorescence analysis of EdU incorporation. Scale bars, 25 μm. The percentage of proliferating
cells was calculated as EdU-positive cells/Hoechst-stained cells × 100%. *p< 0.05 compared with the control (one-way ANOVA followed by Tukey’s HSD
test). D) MPC5 cells were stably transfected with a mouse MKL1 expression plasmid and cultured at 33°C. Expression of MKL1 protein was verified by
western blotting. Actin was used to normalize MKL1 levels. E) At the indicated time points, cell growth was measured using the CCK-8 assay. **p< 0.01
compared with the control (one-way ANOVA followed by Tukey’s HSD test). F) Cell proliferation was measured by immunofluorescence analysis of EdU
incorporation. Scale bars, 25 μm. The percentage of proliferating cells was calculated as EdU-positive cells/Hoechst-stained cells × 100%. *p < 0.05
compared with the control (one-way ANOVA followed by Tukey’s HSD test).
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SRF by binding to the CArG box in the promoter region
of target genes [12,13], we performed a search of the
transcription factor database TRANSFAC and identified
a CArG box (CCTTTTCTGG) at position −316/-307
in the mouse p21 promoter (Figure 4B). Thus, we
assessed whether MKL1 was a bona fide activator of
p21 transcription using reporter gene assays. As shown
in Figure 4C, MKL1 significantly increased mouse p21
promoter activity of the wild-type −1562/+200 re-
porter by approximately 49% relative to the control
without MKL1 transfection. Furthermore, we found
that MKL1 activated the promoter activity of p21 in a
dose-dependent manner (Additional file 4: Figure S4).
A series of truncated p21 promoter-reporter constructs
were thus generated for analysis, as shown in Figure 4B.
The results showed that deletion of the CArG box signifi-
cantly abolished MKL1-induced transactivation of the
p21 promoter compared with that in the control
without MKL1 transfection (Figure 4C). Next, we
prepared mutants of the CArG box (CCTTTTCTGG
to CCTTTTCTTT) by site-directed mutagenesis. We
found that mutation of the CArG box was sufficient to
interfere with MKL1-activated transcription of the p21
promoter (Figure 4D). Chromatin immunoprecipitation(ChIP) assays were then performed using an anti-MKL1
antibody, anti-SRF antibody, or control IgG in MPC5 cells.
The results indicated that both MKL1 and SRF were able
to bind to the p21 promoter during basal conditions in a
CArG-dependent manner (Figure 4E). Overexpression of
MKL1 resulted in a 1.9-fold increase in its binding to the
endogenous p21 promoter in qChIP analysis (Figure 4F).
These results suggested that the overexpressed MKL1 in
conjunction with SRF promotes p21 transcription by bind-
ing to the CArG box in its promoter.
Importantly, to further show that MKL1 regulates podo-
cyte proliferation by targeting p21, MKL1-overexpressing
MPC5 cells (ΔMLK1) were transfected with a p21-
targeting shRNA plasmid (shp21). Expression of MKL1
and p21 was assessed by western blotting (Figure 4G).
The EdU cell proliferation assay revealed a marked de-
crease in the number of cells in S phase after MKL1
overexpression, whereas p21 interference remarkably at-
tenuated the MKL1-inhibited cell cycle progression
through S phase. The percentage of cells in S phase
increased from 41.00% to 67.19% at 48 h after trans-
fection of shp21 in MKL1-overexpressing MPC5 cells
(Figure 4H). These observations confirmed that MKL1
inhibits MPC5 cell proliferation, which is effectively me-
diated by targeting p21.
Figure 3 Knockdown of MKL1 promotes cell cycle progression through S phase. A) MPC5 cells were transiently transfected with a
MKL1-specific shRNA plasmid (shMKL1) or a scrambled shRNA control plasmid (shControl) and cultured at 33°C. The efficiency of MKL1 protein
knockdown was examined by western blotting. Actin was used to normalize MKL1 levels. B) At the indicated time points, cell growth was measured
using the CCK-8 assay. * p < 0.05 and **p < 0.01 compared with the control (one-way ANOVA followed by Tukey’s HSD test). C) Cell proliferation was
measured by immunofluorescence analysis of EdU incorporation. Scale bars, 25 μm. The percentage of proliferating cells was calculated as EdU-positive
cells/Hoechst-stained cells × 100%. *p < 0.05 compared with the control (one-way ANOVA followed by Tukey’s HSD test). D) MPC5 cells were stably
transfected with a MKL1-specific shRNA plasmid (ΔshMKL1) or a scrambled shRNA control plasmid (ΔshControl) and cultured at 33°C. Expression of
MKL1 protein was verified by western blotting. Actin was used to normalize MKL1 levels. E) At the indicated time points, cell growth was measured
using the CCK-8 assay. **p < 0.01 compared with the control (one-way ANOVA followed by Tukey’s HSD test). F) Cell proliferation was measured
by immunofluorescence analysis of EdU incorporation. Scale bars, 25 μm. The percentage of proliferating cells was calculated as EdU-positive
cells/Hoechst-stained cells × 100%. *p < 0.05 compared with the control (one-way ANOVA followed by Tukey’s HSD test).
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in podocytes in vivo
Next, we detected the appearance of MKL1 in develop-
ing podocytes by examining its expression in the new-
born mouse kidney that displays glomeruli at various
stages of development from the S-shaped body through
the capillary loop stage to mature glomeruli [5,6]. Im-
munofluorescence was used to detect MKL1 expression
in the mouse kidney at postnatal day (P) 1, 3, 5, 7, 14,
21, 28 and 49. As seen in Figure 5A b-e, S-shaped and
comma-shaped bodies were observed in the renal cortex
of immature mice at P1–5, ultimately vascularizing intoTable 1 Genes regulated by MKL1
Unigene GeneBank™ accession no. Symbol Description
Mm.195663 NM_007669 Cdkn1a Cyclin-depende
Mm.72235 NM_007836 Gadd45a Growth arrest a
Mm.110220 NM_007837 Ddit3 DNA-damage i
Mm.307932 NM_177733 E2F2 E2F transcriptio
Mm.4815 NM_007628 Ccna1 Cyclin A1a capillary loop of mature nephron at P7. Moreover,
MKL1 expression was found at all stages of renal glom-
erulus and tubule formation during postnatal develop-
ment (Figure 5A b-i). Importantly, there was an increase
in the expression of MKL1 in glomeruli between P5 and
P7 (Figure 5A d-e).
Consequently, to address the correlation between
MKL1 and p21 expression in newborn mouse kidney,
immunofluorescent staining was used to detect p21
expression at P3-28. The results showed a relatively
weak expression of p21 in glomeruli at P3-7 during the
postnatal development (Figure 5B b-d). A remarkableFold change
(MKL1 vs. Control) P value
nt kinase inhibitor 1A (p21) 4.8402 0.0317
nd DNA-damage-inducible 45 alpha 2.9501 0.0268
nducible transcript 3 2.5385 0.0282
n factor 2 -8.3195 0.0146
-6.1312 0.0195
Figure 4 (See legend on next page.)
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Figure 4 MKL1 induces p21 expression. A) The expression of p21 was examined by qPCR and western blotting in MKL1-overexpressing MPC5
cells. GAPDH and actin were used to normalize p21 levels. **p < 0.01 compared with the control (unpaired Student’s t-test). B) Sequential deletions and
mutations of the mouse p21 promoter were fused to a luciferase reporter. MPC5 cells in 24-well plates were co-transfected with the MKL1 expression
plasmid (1 μg/well) and various wild-type C) or mutant D) p21 promoter luciferase reporters (1 μg/well). The luciferase activity of the extracts was
determined at 24 h after transfection using a Betascope analyzer. Luciferase values were normalized to Renilla activities. *p < 0.05 compared with the
empty vector (unpaired Student’s t-test). E) ChIP assays were performed using an anti-MKL1 antibody, anti-SRF antibody, or control IgG in MPC5 cells.
The association of MKL1 or SRF with the proximal mouse p21 promoter was analyzed by PCR. The amount of input was confirmed by equal loading
of chromatin. F) ChIP assays were performed using the anti-MKL1 antibody or control IgG in MKL1-overexpressing MPC5 cells. The association of MKL1
with the proximal mouse p21 promoter was analyzed by PCR or qPCR. The amount of input DNA was confirmed by equal loading of chromatin.
*p < 0.05 compared with the empty vector (unpaired Student’s t-test). G) ΔMKL1 cells were transiently transfected with a p21-specific shRNA plasmid
(shp21) and cultured at 33°C. The efficiency of p21 knockdown was examined by western blotting. Actin was used to normalize MKL1 and p21 levels.
H) Cell proliferation was measured by immunofluorescence analysis of EdU incorporation. Scale bars, 25 μm. The percentage of proliferating cells was
calculated as EdU-positive cells/Hoechst-stained cells × 100%. *p < 0.05 compared with the control (one-way ANOVA followed by Tukey’s HSD test).
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tween P14 and P21 (Figure 5B e-f ), indicating a positive
and sequential correlation between MKL1 and p21 ex-
pression. Considering that podocytes proliferate until
the S-shape body stage and exit the cell cycle at the ca-
pillary loop stage during glomerulogenesis, these results
are consistent with our notion that MKL1 functions as
an effective inducer of cell growth arrest in podocytes,
that might be mediated by the regulation of p21.
Discussion
Growth arrest and differentiation of podocytes are essen-
tial for normal formation of glomeruli in the developingFigure 5 The expression of MKL1 and p21 is correlated in podocytes
staining of the mouse renal cortex at P1 (b), P3 (c), P5 (d), P7 (e), P14 (f), P2
cortex stained with a species-appropriate IgG (a). Scale bar, 50 μm. B) The
mouse renal cortex at P3 (b), P5 (c), P7 (d), P14 (e), P21 (f) and P28 (g). The n
antibody was a species-appropriate IgG (a). Scale bar, 50 μm. The S-shaped
tubule (RT) are indicated.kidney and paramount for normal glomerular function
in the mature kidney. The precise cell cycle regulation
necessary to establish podocyte quiescence during devel-
opment has not been fully defined. In the present study,
we identified the contribution of one of the myocardin/
MKL proteins, MKL1, to the regulation of MPC5 cell
proliferation. During temperature-switched growth ar-
rest of MPC5 cells, MKL1 expression was significantly
upregulated above its other family members. Conse-
quently, experiments were performed to assess gain- and
loss-of-function of MKL1 to study the effect of MKL1
on MPC5 cell proliferation. We found that overexpres-
sion of MKL1 resulted in significant repression of G1/Sin vivo. A) MKL1 expression was examined by immunofluorescence
1 (g), P28 (h), and P49 (i). The negative control image shows the renal
expression of p21 was examined by immunofluorescent staining in the
egative control image was from the renal cortex, in which the primary
body (SSB), comma-shaped body (CSB), capillary loop (CL), and renal
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knockdown had the opposite effect. Importantly, we
demonstrated that MKL1 activated transcription of the
cell cycle inhibitor p21 by recruitment to its promoter in
a CArG element-dependent manner. In addition, MKL1
expression in the mouse kidney during postnatal devel-
opment showed that MKL1 is expressed in podocytes
in vivo, which was significantly upregulated during the
morphological switch of podocytes from proliferation to
differentiation.
Recent evidence supports an important and complex
role of MKL1 in maintenance of proper differentiation
in various cell lines including smooth muscle cells [30],
myofibroblasts [31], megakaryocytes [22], and adipocytes
[32]. Whether MKL1 functions in cell proliferation,
however, remains poorly understood. Shaposhnikov
et al. reported that MKL1 regulates the expression levels
of two proapoptotic Bcl-1 family members, Bok and
Noxa, and thus is involved in apoptotic signaling in
NIH3T3 fibroblasts [33]. Here, we extended the study to
show that elevated expression of MKL1 significantly
blocked cell cycle progression by decreasing the number
of MPC5 cells in S phase. On the other hand, RNA
interference of MKL1 expression resulted in the opposite
effect to promote G1/S transition of the cell cycle, con-
firming a potential role of MKL1 in regulation of cell
proliferation. These observations collectively position
MKL1 as a potential regulatory factor at the crossroad
between cell proliferation and differentiation.
Indeed, myocardin family members have been previ-
ously implicated in the regulation of cell proliferation.
Myocardin impairs the proliferation of vascular smooth
muscle cells, Chinese hamster ovarian (CHO) cells, and
leiomyosarcoma cells [27,28]. In HT1080 fibrosarcoma
cells, myocardin inhibits proliferation at a low cell dens-
ity and abrogates colony formation in soft agar [34].
However, the suggested molecular mechanisms under-
lying myocardin/MKL-induced cell growth arrest are
conflicting. In human uterine leiomyosarcoma cells,
myocardin in conjunction with SRF directly binds to the
p21 promoter and induces its expression, thus resulting
in G1/S arrest [27]. In contrast, myocardin has been
shown to downregulate expression of c-myc, CDK1,
CDK2, and S6K, but not p21 and p27, which leads to
G2/M arrest and accumulation of polyploidy cells [35].
Our data presented here support the notion that MKL1
functions as an effective regulator to inhibit cell prolifer-
ation by altering p21 expression in MPC5 cells. Signifi-
cant upregulation of p21 expression at both mRNA and
protein levels was observed after transfecting the MKL1
expression plasmid, whereas MKL1 interference resulted
in the opposite effect to downregulate p21 expression
(Additional file 5: Figure S5), suggesting that a direct
mechanism is involved in this regulation. We furtherdemonstrated that MKL1 induced promoter activity of
the p21 gene in a dose-dependent manner. Importantly,
we found that deletion or mutation of the CArG elem-
ent in the mouse p21 promoter remarkably abolished
the stimulatory effect on p21 transcription induced by
MKL1. Transfection of the MKL1 expression plasmid
led to a marked increase in the binding affinity of MKL1
for the endogenous p21 promoter, indicating a significant
role of the CArG element in mediating MKL1-induced ex-
pression of p21. In addition to p21, we identified obvious
candidates involved in MKL1-regulated MPC5 cell prolif-
eration, such as Gadd45a, Ddit3, E2F2, and cyclin A1.
However, these genes are not potential targets of myocar-
din/MKLs/SRF (unpublished data). These results indicate
that an SRF-independent mechanism might contribute to
MKL-mediated G1/S arrest of the cell cycle.
In the present study, we found that MKL1 was
expressed in podocytes of the mouse kidney during post-
natal development. Moreover, a significant increase in
MKL1 expression was observed between P5 and P7 dur-
ing postnatal development of the kidney, highlighting
a potential role of MKL1 in the physiological and mor-
phological switch of podocytes from proliferation to
differentiation. Therefore, using the conditionally im-
mortalized mouse podocyte cell line MPC5, we further
revealed that MKL1 functioned as an effective inducer
to inhibit cell proliferation and trigger cell cycle arrest at
G1/S transition. Several studies have also demonstrated
the presence of an intrinsic barrier to replication associ-
ated with activation of the cell cycle in podocytes.
Re-expression of cell cycle proteins has been reported
during glomerular disorders. De novo cyclin A staining is
observed in podocytes of children with collapsing glo-
merulopathy [36] and focal segmental glomerulosclerosis
(FSGS) [37]. Positive signals for cyclin D have also been
reported in the cellular lesions of FSGS [38]. Recently,
strong upregulation of CKIs p21 and p27 was reported in
podocytes during Heymann nephritis and in diabetic
ZDF-fa/fa rats [39,40]. Moreover, the glomerular tufts in
crescentic glomerulonephritis strongly express CKIs [41],
suggesting that podocytes upregulate CKIs to maintain
cell cycle quiescence and preserve normal physiological
functions. Here, we extended the study showing that
MKL1 acted as an upstream regulator of a variety of cell
cycle factors, such as p21 and cyclin A1, to control cell
cycle progression in podocytes. In addition, we found sig-
nificant upregulation of MKL1 expression in the renal
tubular cells of newborn mouse kidneys. Recent reports
have revealed a potential role of MKL1 in the regulation
of renal tubular diseases. For example, Xu et al. reported
that MKL1 is induced by glucose and synergizes with glu-
cose to induce collagen expression in cultured renal
tubular epithelial cells and the kidneys of mice with dia-
betic nephropathy, eventually leading to tubulointerstitial
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(SCAI) has been demonstrated to negatively regulate
epithelial-mesenchymal transition and renal fibrosis in
LLC-PK1 (CL4) proximal tubular epithelial cells, which is
at least partially mediated by repression of MKL1 and
MKL2 [43]. Taken together, these observations indicate
that MKL1 performs physiological roles in maturation
and development of the kidney, and thus its dysfunction
might lead to glomerular and renal diseases.
Conclusion
In the present study, we found a potential mechanism of
MKL1/p21-mediated cell cycle quiescence in podocytes.
Therefore, these findings reveal a novel function of
MKL1 during podocyte proliferation and differentiation,
furthering our understanding of kidney development
and the mechanisms of kidney diseases.
Methods
Plasmid construction
The mouse p21 promoter sequence (−1562/+200) was
obtained by PCR from mouse blood genomic DNA and
cloned into the pGL3-basic vector (Promega) using the
forward primer, 5′-AGCAAGAATTCACAGACCGATG-
3′, and reverse primer, 5′-GTACCTGACACATACA
CACC-3′. The mutagenesis of the CArG box in the
mouse p21 promoter was performed using the Quick-
Change Site-Directed Mutagenesis Kit (Stratagene) with
the forward primer: 5′-gtactcccctgtCCTTTTCTTT
gaagtggtgatt-3′ and reverse primer: 5′-aatcaccacttc
AAAGAAAAGGacaggggagtac-3′.
Cell culture and transfection
MPC-5 cells were propagated in collagen I-coated dishes
at 33°C (permissive temperature) in RPMI supplemented
with 10% FBS and 20 U/ml of recombinant mouse
IFN-γ (R&D). To induce differentiation, the medium was
changed to RPMI with 5% FBS without IFN-γ, and the cells
were shifted to 37°C (nonpermissive temperature) for
10 days. Under these conditions, cells underwent growth
arrest, increased in size, and developed elongated cell
processes. The cells were transfected using TurboFect™
Transfection Reagent (Fermentas) according to the manu-
facturer’s protocols.
The mouse MKL1 expression plasmid was introduced
into MPC5 by transient transfection. G418-resistant
clones were isolated over a period of 3–4 weeks. The
overexpression of MKL1 was confirmed by western blot-
ting assay.
Cell viability assay
MPC5 cells transfected with the mouse MKL1 expres-
sion plasmid or empty vector were seeded onto 96-well
plates at a density of 2 × 103 cells/well and incubated inRPMI containing 5% FBS at 33°C for 6 days. The cell
viability was assessed using the CCK-8 assay according
to the manufacturer’s protocols (Dojindo). Six parallel
replicates were measured for each sample.
5-ethynyl-2′-deoxyuridine (EdU) cell proliferation assay
MPC5 cells transfected with the mouse MKL1 expres-
sion plasmid or empty vector were seeded onto 24-well
plates at 50-60% confluence. Cells were incubated with
50 μM EdU for 2 h at 48–72 h after transfection. After
the 2-h pulse, the cells were washed twice with PBS and
fixed with 4% paraformaldehyde at room temperature
for 30 min. The cells were subsequently washed with
glycine (2 mg/ml) for 5 min, added 0.2% Trion X-100
for 10 min, washed with PBS twice, and added click re-
action buffer (Tris–HCl, pH 8.5, 100 mM; CuSO4,
1 mM; Apollo 550 fluorescent azide, 100 mM; ascorbic
acid, 100 mM) for 30 min while protecting from light.
The cells were then washed again with 0.5% Triton X-
100 for three times, stained with Hoechst (5 mg/ml) for
30 min at room temperature, washed with 0.5% Triton
X-100 for three times. Images were taken and analyzed
using Confocal FV1000 (Olympus). EdU positive cells
were calculated with (EdU add-in cells/Hoechst stained
cells) × 100%. At least 200 cells were counted per well.
RNA extraction and quantitative RT-PCR
Using TRIzol Reagent (Invitrogen), total RNA was ex-
tracted from MPC5 cells that were cultured at the non-
permissive temperature of 37°C for 10 days. Total RNA
(0.5 μg) from each sample was used for first-strand
cDNA synthesis using M-MLV Reverse Transcriptase
(Promega). The specific products of mouse myocardin,
MKL1 and MKL2 were amplified by quantitative PCR
using the following primers: myocardin, 5′-GATGGG
CTCTCTCCAGATCAG-3′ (forward) and 5′-GGCTGC
ATCATTCTTGTCACTT-3′ (reverse); MKL1, 5′-CCCA
AAGGTAGCAGACAGTTC-3′ (forward) and 5′-GAGT
GGGTGATATGGAGGTGG-3′ (reverse); and MKL2,
5′-GAGCGAGCCAGAACTGAGAAT-3′ (forward) and
5′-ACTCGAATCCACAGGAAGGATG-3′ (reverse). The
verification of gene expression levels was performed by
quantitative RT-PCR using EvaGreen (Biotium). GAPDH
was used as an internal control.
Western blotting and antibodies
Whole cell extract preparation and western blotting
with the appropriate antibodies were performed as previ-
ously described [44]. The following antibodies (Abs)
were used: rabbit polyclonal Ab against MKL1 at 1:800
dilution (ab49311; Abcam), rabbit polyclonal Ab against
p21 at 1:500 dilution (10355-1-AP; Proteintech) and
mouse monoclonal Ab against actin at 1:1000 dilution
(A-4700; Sigma).
Yang et al. BMC Molecular Biology  (2015) 16:1 Page 10 of 12RT2 Profiler™ PCR array
Total RNA was extracted from MPC5 cells stably trans-
fected with the mouse MKL1 expression plasmid
(ΔMKL1) or empty vector (ΔControl). For PCR array
experiments, an RT2 Profiler custom PCR array was
used to simultaneously examine the mRNA levels of
84 genes closely associated with cell cycle, including 5
“housekeeping genes”, in 96-well plates following the
manufacturer’s protocol (PAMM-020Z, QIAGEN). Briefly,
first-strand cDNAs were synthesized from 1 μg of total
RNA using the TaqMan RT reagent kit (QIAGEN) accord-
ing to the manufacturer’s protocol. The reaction mixtures
(25 μl) were incubated at 25°C for 10 min, followed by in-
cubation at 48°C for 30 min and 95°C for 5 min, then
cooled on ice. Arrays were performed independently at
least three times for each cell line; values were obtained
for the threshold cycle (Ct) for each gene and normalized
using the average of five housekeeping genes on the same
array (Actb, B2m, Gapdh, Gusb, and Hsp90ab1). The Ct
values for housekeeping genes and a dilution series of
ACTB were monitored for consistency between the arrays.
The change (ΔCt) between ΔMKL1 and ΔControl was de-
termined using the formula ΔCt = Ct(ΔMKL1) – Ct
(ΔControl), and the fold change was determined using the
formula fold change = 2(−ΔCt). The resulting values were
reported as fold change; only genes showing twofold or
greater change were considered. The negative controls en-
sured the absence of DNA contamination and set the
threshold for determining absence versus presence of
expression.
Luciferase assay
MPC5 cells were co-transfected with the wild-type or
mutant mouse p21 promoters and MKL1 expression
plasmid in 24-well plates. Lysates were prepared at 24 h
after transfection, and luciferase activities were mea-
sured using the Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer’s protocols.
The luciferase activities were normalized to the values
for Renilla luciferase.
Chromatin immunoprecipitation (CHIP)
ChIP assays were performed using reagents commer-
cially obtained from Upstate, essentially according to the
manufacturer’s instructions. The antibodies used in these
experiments were rabbit polyclonal Ab against MKL1
(ab49311; Abcam) and anti-rabbit normal IgG (sc-2345,
Santa Cruz). The amounts of each specific DNA frag-
ment in immunoprecipitates were determined by PCR
or quantitative PCR reactions. The fragment of mouse
p21 promoter, containing the CArG box, was ampli-
fied using the forward primer: 5′-CCCTCGTGCTTA
GACCA-3′, and reverse primer: 5′-GCTGTTGCTGC
TACCCA-3′.Immunofluorescent analysis
Tissue samples were placed in 4% paraformaldehyde in
PBS over 2 hours at 4°C, immersed in 30% sucrose over-
night at 4°C, and then were embedded in OCT com-
pound (Tissue-Tek, Miles) and sectioned at 5 mm (Leica
CM 1850, Leica Instruments) for the morphological and
immunohistochemistry study. Sections were washed
three times in PBS for five minutes each and incubated
in blocking buffer with 10% serum of the secondary anti-
body host species for 1 hour at room temperature. After
that, sections were incubated with rabbit polyclonal Ab
against MKL1 (ab49311; Abcam) and p21 (10355-1-AP;
Proteintech) at 1:100 dilution overnight at 4°C. After
being washed three times for 10 minutes with PBS at
room temperature, sections were incubated with Alexa
488-conjugated anti-rabbit IgG for 3 hours at room
temperature. Negative control samples were treated with
species-appropriate IgG instead of primary antibody. Im-
ages were taken and analyzed using Confocal FV1000
(Olympus).Statistical analysis
SPSS 17.0 software (SPSS) was used for statistical ana-
lysis. The data from all the experiments are presented as
means ± SD and represent three independent experi-
ments. One-way analysis of variance (ANOVA) was used
to compare means between treatment groups and
Tukey’s HSD (honestly significant difference) test was
used to evaluate the statistically significant differences
between groups. Where appropriate, Student’s t-test for
unpaired observations was applied. A p-value < 0.05 was
considered significant.Additional files
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